POM Issues Emergency Use Permit for COVOVAX COVID-19 Vaccine
The Indonesian Food and Drug Administration (FDA) has issued another emergency use permit (EUA) on Nov 17, 2021 for COVOVAX COVID-19 Vaccine.
The 11th COVID-19 vaccine to receive EUA in Indonesia is manufactured by Serum Institute of India Pvt. Ltd, India (SII) and will be intended for adults aged 18 years and above.
The vaccine is administered twice with an interval of 21 days between the first and second doses, and each dose is injected at 5 mg per dose.
It is known that the side effects (KIPI) of Covovax are mild to moderate, namely local pain, tenderness, headache, fatigue, muscle pain/myalgia, and fever.
The efficacy in those aged 18 years and above was between 89.7%-90.4% for various levels of severity and ranged between 86.9%-100% for moderate-severe severity. Meanwhile, the efficacy in elderly vaccine recipients is known to reach 88.9% in the UK.
For information related to COVID-19 visit the official website of COVID-19 Handling and National Economic Recovery https://covid19.go.id and https://s.id/infovaksin
#IndonesiaRises #EVERYONEMustHaveAIMASKER
Detail:
- Tipe: Image
- Format: JPEG/PNG
- Jumlah File: 2
